Ergomed plc, a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Roy Ovel as Chief Commercial Officer with immediate effect.
The European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its first meeting in Amsterdam.